Associations between APOE and low-density lipoprotein cholesterol genotypes and cognitive and physical capability: the HALCyon programme
- PMID: 25073452
- PMCID: PMC4150901
- DOI: 10.1007/s11357-014-9673-9
Associations between APOE and low-density lipoprotein cholesterol genotypes and cognitive and physical capability: the HALCyon programme
Abstract
The APOE ε2/3/4 genotype has been associated with low-density lipoprotein cholesterol (LDL-C) and Alzheimer disease. However, evidence for associations with measures of cognitive performance in adults without dementia has been mixed, as it is for physical performance. Associations may also be evident in other genotypes implicated in LDL-C levels. As part of the Healthy Ageing across the Life Course (HALCyon) collaborative research programme, genotypic information was obtained for APOE ε2/3/4, rs515135 (APOB), rs2228671 (LDLR) and rs629301 (SORT1) from eight cohorts of adults aged between 44 and 90 + years. We investigated associations with four measures of cognitive (word recall, phonemic fluency, semantic fluency and search speed) and physical capability (grip strength, get up and go/walk speed, timed chair rises and ability to balance) using meta-analyses. Overall, little evidence for associations between any of the genotypes and measures of cognitive capability was observed (e.g. pooled beta for APOE ε4 effect on semantic fluency z score = -0.02; 95 % CI = -0.05 to 0.02; p value = 0.3; n = 18,796). However, there was borderline evidence within studies that negative effects of APOE ε4 on nonverbal ability measures become more apparent with age. Few genotypic associations were observed with physical capability measures. The findings from our large investigation of middle-aged to older adults in the general population suggest that effects of APOE on cognitive capability are at most modest and are domain- and age-specific, while APOE has little influence on physical capability. In addition, other LDL-C-related genotypes have little impact on these traits.
References
Publication types
MeSH terms
Substances
Grants and funding
- MC_UP_A620_1015/MRC_/Medical Research Council/United Kingdom
- R01 HL036310/HL/NHLBI NIH HHS/United States
- BHF_/British Heart Foundation/United Kingdom
- MC_UU_12011/2/MRC_/Medical Research Council/United Kingdom
- MC_UU_12019/1/MRC_/Medical Research Council/United Kingdom
- G0601333/MRC_/Medical Research Council/United Kingdom
- R01 AG034454/AG/NIA NIH HHS/United States
- MR/K026992/1/MRC_/Medical Research Council/United Kingdom
- MC_UP_A620_1014/MRC_/Medical Research Council/United Kingdom
- HL36310/HL/NHLBI NIH HHS/United States
- ARC_/Arthritis Research UK/United Kingdom
- G0000934/MRC_/Medical Research Council/United Kingdom
- R01AG034454/AG/NIA NIH HHS/United States
- R01AG013196/AG/NIA NIH HHS/United States
- ETM/55/CSO_/Chief Scientist Office/United Kingdom
- CZB/4/505/CSO_/Chief Scientist Office/United Kingdom
- K013351/MRC_/Medical Research Council/United Kingdom
- AG1764406S1/AG/NIA NIH HHS/United States
- 068545/Z/02/WT_/Wellcome Trust/United Kingdom
- MR/K013351/1/MRC_/Medical Research Council/United Kingdom
- R01 AG013196/AG/NIA NIH HHS/United States
- MC_UU_12011/1/MRC_/Medical Research Council/United Kingdom
- R01HL36310/HL/NHLBI NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- 15/SAG09977/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- BB/F019394/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- GR068468MA/WT_/Wellcome Trust/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous